Currently out of the existing stock ratings of Aydin Huseynov, 54 are a BUY (85.71%), 9 are a HOLD (14.29%).

Aydin Huseynov

Work Performance Price Targets & Ratings Chart

Analyst Aydin Huseynov, currently employed at LADENBURG, carries an average stock price target met ratio of 21.83% that have a potential upside of 34.06% achieved within 85 days.

Aydin Huseynov’s has documented 112 price targets and ratings displayed on 22 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on MRKR, Marker Therapeutics at 21-Oct-2024.

Wall Street Analyst Aydin Huseynov

Analyst best performing recommendations are on TPST (TEMPEST THERAPEUTICS).
The best stock recommendation documented was for INO (INOVIO PHARMACEUTICALS) at 1/8/2021. The price target of $15 was fulfilled within 24 days with a profit of $5.78 (62.69%) receiving and performance score of 26.12.

Average potential price target upside

of $180.5 (47.73%) on PALI (PALISADE BIO).
of $71.28 (12.5%) on REGN (REGENERON PHARMACEUTICALS).
of $5.76 (258.17%) on TPST (TEMPEST THERAPEUTICS).

CALA Calithera Biosciences INCY yte INO Inovio Pharmaceuticals NKTR Nektar Therapeutics REGN Regeneron Pharmaceuticals SLS Sellas Life Sciences Group SPRB Spruce Biosciences VYGR Voyager Therapeutics NXTC NextCure ALLR Allarity Therapeutics ATHE Alterity Therapeutics Ltd CMPX Compass Therapeutics PCSA Processa Pharmaceuticals TRIL Trillium Therapeutics PALI Palisade Bio CRVS Corvus Pharmaceuticals CGTX Cognition Therapeutics TPST Tempest Therapeutics CAPR Capricor Therapeutics MRKR Marker Therapeutics ACRV Acrivon Therapeutics, Common Stock ALRN Aileron Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Jonathan Chang (LEERINK)